Compare Moody's Corporation (MCO) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moody's Corporation vs Organon & Co. Common Stock — how do they compare? Moody's Corporation trades at $462.77 (market cap $80.38B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Moody's Corporation is far larger — about 22.2× Organon & Co. Common Stock's market cap, and Moody's Corporation pays the higher dividend (0.89%). Which is the better fit depends on your goals — on Pluang, investors hold Moody's Corporation for 133 Days and Organon & Co. Common Stock for 0 Days on average.
| MCO | OGN | |
|---|---|---|
Market Cap | $80.38B | $3.62B |
Volume | 628,586 | 2,892,999 |
Sector | Financials | Health |
52-Week High | $539.61 | $13.81 |
52-Week Low | $412.23 | $5.70 |
Typical Hold Time | 133 Days | 0 Days |
Enterprise Value | $86.40B | $11.04B |
Dividend Yield | 0.89% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moody's Corporation (MCO) trades at $462.77, down 1.64% on the day, as the stock consolidates near key support. The company maintains strong fundamentals with revenue reaching $7.72B in 2025 and net income margin expanding to 34.25%. Recent earnings beats and a bullish technical signal underscore positive momentum, while analyst consensus remains favorable with a $536.40 price target. Strategic moves like the PhilRatings stake and Google Cloud partnership highlight growth initiatives in the Asia-Pacific region and financial services technology.
Outlook: Moody's exhibits robust profitability and strategic expansion, supporting a positive investment case. Risks include high valuation multiples (P/E 29.45) and sensitivity to credit cycle fluctuations. The stock offers growth potential but requires monitoring of debt levels and macroeconomic trends affecting its credit rating business.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Moody's Corporation
Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.
Read more on MCO →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
